Search results for "dalit"

showing 10 items of 1091 documents

Thoracic ultrasound: Potential new tool for physiotherapists in respiratory management. A narrative review

2016

International audience; The use of diagnostic ultrasound by physiotherapists is not a new concept; it is frequently performed in musculoskeletal physiotherapy. Physiotherapists currently lack accurate, reliable, sensitive, and valid measurements for the assessment of the indications and effectiveness of chest physiotherapy. Thoracic ultrasound may be a promising tool for the physiotherapist and could be routinely performed at patients' bedsides to provide real-time and accurate information on the status of pleura, lungs, and diaphragm; this would allow for assessment of lung aeration from interstitial syndrome to lung consolidation with much better accuracy than chest x-rays or auscultation…

Lung DiseasesPleural effusionMechanical Ventilationmedicine.medical_treatmentFollow-UpM-Mode SonographyCritical Care and Intensive Care MedicineCritically-Ill Patients0302 clinical medicineOutcome Assessment Health CareMedicineCommunity-Acquired Pneumonia030212 general & internal medicineIntensive-CareLungPhysiotherapyUltrasonographymedicine.diagnostic_testUltrasound3. Good healthDiaphragm (structural system)Lung UltrasoundChestRadiography ThoracicRespiratory therapymedicine.medical_specialtyCritical CarePoint-of-Care SystemsDiaphragmChest physiotherapy03 medical and health sciencesIntensive care[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyUltrasoundHumansIntensive care medicineObstructive Pulmonary-DiseasePhysical Therapy ModalitiesMechanical ventilationbusiness.industryAuscultationSemiologymedicine.diseaseRespiration DisordersDiaphragmatic MovementPleural EffusionOutcome assessment030228 respiratory systemPhysical therapybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Diagnosis, assessment, and management of surgical complications following esophagectomy

2018

Despite improvements in operative strategies for esophageal resection, anastomotic leaks, fistula, postoperative pulmonary complications, and chylothorax can occur. Our review seeks to identify potential risk factors, modalities for early diagnosis, and novel interventions that may ameliorate the potential adverse effects of these surgical complications following esophagectomy. ispartof: Annals of the New York Academy of Sciences vol:1434 issue:1 pages:254-273 ispartof: location:United States status: Published online

Lung Diseasesmedicine.medical_specialtycomplicationsFistulamedicine.medical_treatmentanastomotic leakAnastomotic LeakGeneral Biochemistry Genetics and Molecular BiologyThoracic duct03 medical and health sciencesEsophagus0302 clinical medicineHistory and Philosophy of SciencechylothoraxmedicineHumansfistulaesophageal cancerEsophagusAdverse effectModalitiesbusiness.industryGeneral NeuroscienceChylothoraxEsophageal cancermedicine.diseaseSurgeryEsophagectomymedicine.anatomical_structureEsophagectomy030220 oncology & carcinogenesis030211 gastroenterology & hepatologybusinessAnnals of the New York Academy of Sciences
researchProduct

Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors

2014

Abstract: Introduction: Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) yields tumour responses in non-small cell lung cancer (NSCLC) patients harbouring activating EGFR mutations. However, even in long-lasting responses, resistance to EGFR TKIs invariably occurs. Areas covered: This review examines resistance mechanisms to EGFR TKI treatment, which mainly arise from secondary EGFR mutations. Other resistance-inducing processes include mesenchymal-epithelial transition factor (MET) amplification, epithelial-mesenchymal transformation, phenotypic change from NSCLC to small-cell lung carcinoma, and modifications in parallel signalling pathways. Current…

Lung NeoplasmsSettore MED/06 - Oncologia MedicaAfatinibNovel therapeutic strategiesLapatinibmedicine.disease_causeNSCLCT790Mchemistry.chemical_compoundErbB ReceptorsCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsHumansRadiology Nuclear Medicine and imagingEpidermal growth factor receptorProtein Kinase InhibitorsEGFR inhibitorsbiologybusiness.industryEGFR mutations; TKI inhibitors resistance; NSCLC; New drugs; Novel therapeutic strategiesGeneral MedicineNew drugEGFR mutationsCombined Modality TherapyDacomitinibrespiratory tract diseasesErbB ReceptorsNew drugsOncologychemistryDrug Resistance NeoplasmCancer researchbiology.proteinKRASHuman medicineEGFR mutationbusinessmedicine.drugTKI inhibitors resistanceCancer Treatment Reviews
researchProduct

Emerging drugs for the treatment of vitiligo.

2020

Introduction: Vitiligo is a relatively common autoimmune depigmenting disorder of the skin. There has been a great advance in understanding the pathological basis, which has led to the development and utilization of various new molecules in treating vitiligo. This review aims at a comprehensively describing the treatments available and the emerging treatment aspects and the scope for future developments.Areas covered: This study comprehensively summarizes the current concepts in the pathogenesis of vitiligo with special focus on the cytokine and signaling pathways, which are the targets for newer drugs. JAK kinase signaling pathways and the cytokines involved are the focus of vitiligo treat…

MAP Kinase Signaling SystemAdministration TopicalVitiligoAdministration OralVitiligoBiologicsBioinformatics030226 pharmacology & pharmacy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineClinical Trials Phase II as TopicLocalized vitiligoMedicineHumansJanus Kinase InhibitorsPharmacology (medical)skin and connective tissue diseasesRandomized Controlled Trials as TopicPharmacologytreatmentintegumentary systembusiness.industrymedicine.diseaseCombined Modality TherapyJAK inhibitorchemistryClinical Trials Phase III as Topic030220 oncology & carcinogenesisCytokinesAfamelanotideDermatologic AgentsbusinessJanus kinaseBiologics; JAK inhibitor; treatment; vitiligoExpert opinion on emerging drugs
researchProduct

An Automatic Sleep Scoring Toolbox : Multi-modality of Polysomnography Signals’ Processing

2019

Sleep scoring is a fundamental but time-consuming process in any sleep laboratory. To speed up the process of sleep scoring without compromising accuracy, this paper develops an automatic sleep scoring toolbox with the capability of multi-signal processing. It allows the user to choose signal types and the number of target classes. Then, an automatic process containing signal pre-processing, feature extraction, classifier training (or prediction) and result correction will be performed. Finally, the application interface displays predicted sleep structure, related sleep parameters and the sleep quality index for reference. To improve the identification accuracy of minority stages, a layer-w…

MATLABSpeedupComputer scienceFeature extraction02 engineering and technologyPolysomnographyMachine learningcomputer.software_genreuni (lepotila)polysomnography0202 electrical engineering electronic engineering information engineeringmedicineHidden Markov modelSignal processingSleep Stagesmedicine.diagnostic_testbusiness.industrysignaalianalyysi020206 networking & telecommunicationsautomatic sleep scoringToolboxmulti-modality analysis020201 artificial intelligence & image processingArtificial intelligencebusinesscomputerClassifier (UML)MATLAB toolbox
researchProduct

[Exercices program and rehabilitation of motor disorders in Parkinson's disease].

2000

International audience; As long as motor disorders are controlled by DOPAtherapy, exercise programs and rehabilitation would not appear to be essential for patients suffering from Parkinson's disease. Such measures do become necessary however when secondary occurrence of motor decline develops. Physical medicine and rehabilitation have not been really involved in Parkinson's disease and few articles have assessed the value of these programs. In fact, controlled randomized studies have faced two kinds of methodological difficulties, those due to rehabilitation practices, and those due to Parkinson's disease specificity, especially similarities between groups for Hoehn and Yahr stage at study…

MESH: HumansMovement DisordersMESH : Humans[SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive SciencesParkinson DiseaseMESH : Exercise TherapyExercise Therapy[ SDV.NEU.SC ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive SciencesMESH : Parkinson DiseaseMESH : Physical Therapy ModalitiesMESH : Movement DisordersMESH: Exercise TherapyHumans[SDV.NEU.SC] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive SciencesMESH: Movement DisordersMESH: Parkinson DiseasePhysical Therapy ModalitiesMESH: Physical Therapy ModalitiesRevue neurologique
researchProduct

'I giovani adulti presi in carico dagli USSM siciliani. I risultati di una ricerca empirica'

2013

MODALITA' DI TRATTAMENTOPERFORMATIVITA' DEGLI OPERATORISettore SPS/08 - Sociologia Dei Processi Culturali E ComunicativiCIRCUITO PENALE MINORILEPERFORMATIVITA' DEL SISTEMA PENALE MINORILE
researchProduct

Multi-factorial sicilian modals: a case of continuity in discourse

2008

We intend to analyze a few constructions, in Sicilian (S) and in the variety of Italian spoken in Sicily (IS), involving the modals voliri (S)/volere (IS) “want” and aviri a (S)/dovere (IS) “have to”. They are used to express both modal values, along a deontic→epistemic continuum, and futurity (Sicilian, but not Italian, lacks a synthetic future). Modality has been traditionally defined as the linguistic manifestation of the speaker’s attitude towards his utterance. However, modality does not have an unambiguous treatment and there is no agreement on number and kind of semantic categories that can be completely defined as modals (cf. Bybee et al. 1994; Palmer 2001; Nuyts 2005). From a cogni…

MODALITYCOGNITIVE LINGUISTICSSICILIANSettore L-LIN/01 - Glottologia E Linguistica
researchProduct

Use of psycho‐oncological services by prostate cancer patients: A multilevel analysis

2020

Abstract Background Cancer patients often suffer from psychological distress. Psycho‐oncological services (POS) have been established in some health care systems in order to address such issues. This study aims to identify patient and center characteristics that elucidate the use of POS by patients in prostate cancer centers (PCCs). Methods Center‐reported certification and patient survey data from 3094 patients in 44 certified PCCs in Germany were gathered in the observational study (Prostate Cancer Outcomes). A multilevel analysis was conducted. Results Model 1 showed that utilization of POS in PCCs is associated with patients’ age (OR = 0.98; 95%‐CI = 0.96‐0.99; P < .001), number of como…

Male0301 basic medicineCancer Researchmedicine.medical_treatmentprostate neoplasmsAndrogen deprivation therapyProstate cancer0302 clinical medicineProspective StudiesOriginal ResearchAged 80 and overProstatectomyHealth services researchpsychosocial oncologyMiddle AgedPrognosisprostate cancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCombined Modality Therapyhealth services researchOncology030220 oncology & carcinogenesismultilevel analysisAdultmedicine.medical_specialtyPsycho-Oncologylcsh:RC254-28203 medical and health sciencesInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingWatchful WaitingAgedProstatectomybusiness.industryPsychosocial Support SystemsProstatic NeoplasmsClinical Cancer ResearchCancerAndrogen Antagonistsmedicine.diseasePsychotherapy030104 developmental biologypsycho‐oncologyProstate neoplasmObservational studybusinessWatchful waitingFollow-Up StudiesCancer Medicine
researchProduct

KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma

2021

Despite curative-intent treatment, most patients with locally advanced esophageal cancer will experience disease recurrence or locoregional progression, highlighting the need for new therapies. Current guidelines recommend definitive chemoradiotherapy in patients ineligible for surgical resection, but survival outcomes are poor. Pembrolizumab is well tolerated and provides promising antitumor activity in patients with previously treated, advanced, unresectable esophageal/esophagogastric junction cancer. Combining pembrolizumab with chemoradiotherapy may further improve outcomes in the first-line setting. Here, we describe the design and rationale for the double-blind, Phase III, placebo-co…

Male0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyClinical Trial ProtocolEsophageal Neoplasmsesophageal adenocarcinomamedicine.medical_treatmentPembrolizumabAntibodies Monoclonal Humanizedchemotherapy03 medical and health sciences0302 clinical medicineClinical ProtocolsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansesophageal cancerradiotherapyChemotherapybusiness.industryCancerChemoradiotherapyGeneral MedicineEsophageal cancermedicine.diseaseCombined Modality Therapyesophageal squamous cell carcinomaRadiation therapyClinical trial030104 developmental biologyOncologyResearch Design030220 oncology & carcinogenesisFemaleimmunotherapypembrolizumabbusinessChemoradiotherapyFuture Oncology
researchProduct